Lyell Immunopharma (LYEL) Expected to Announce Earnings on Monday

Lyell Immunopharma (NASDAQ:LYEL - Get Free Report) is anticipated to post its Q1 2025 quarterly earnings results before the market opens on Monday, May 5th. Analysts expect the company to announce earnings of ($0.19) per share for the quarter.

Lyell Immunopharma (NASDAQ:LYEL - Get Free Report) last posted its quarterly earnings results on Wednesday, March 12th. The company reported ($0.72) EPS for the quarter, missing the consensus estimate of ($0.20) by ($0.52). The business had revenue of $0.01 million during the quarter. Lyell Immunopharma had a negative net margin of 323,792.09% and a negative return on equity of 34.64%. On average, analysts expect Lyell Immunopharma to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Lyell Immunopharma Stock Performance

NASDAQ:LYEL traded up $0.04 during mid-day trading on Wednesday, hitting $0.48. 1,021,438 shares of the company's stock traded hands, compared to its average volume of 1,041,970. The company has a market cap of $140.34 million, a PE ratio of -0.60 and a beta of -0.26. The firm's 50 day simple moving average is $0.54 and its 200 day simple moving average is $0.72. Lyell Immunopharma has a 1 year low of $0.39 and a 1 year high of $2.88.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reaffirmed a "neutral" rating and issued a $1.00 price objective on shares of Lyell Immunopharma in a research note on Wednesday, April 16th.

Insider Transactions at Lyell Immunopharma

In related news, CFO Charles W. Newton bought 200,000 shares of Lyell Immunopharma stock in a transaction dated Monday, March 17th. The stock was acquired at an average cost of $0.56 per share, with a total value of $112,000.00. Following the completion of the acquisition, the chief financial officer now directly owns 200,000 shares in the company, valued at approximately $112,000. This trade represents a ∞ increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Lynn Seely acquired 175,000 shares of the business's stock in a transaction on Friday, March 14th. The shares were bought at an average price of $0.61 per share, for a total transaction of $106,750.00. Following the acquisition, the chief executive officer now owns 712,500 shares in the company, valued at approximately $434,625. This trade represents a 32.56 % increase in their position. The disclosure for this purchase can be found here. In the last ninety days, insiders have purchased 768,640 shares of company stock worth $449,508. 25.10% of the stock is currently owned by company insiders.

About Lyell Immunopharma

Lyell Immunopharma, Inc, a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic.